Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma

Cancer Discovery

Volumn 4, Issue 12, 2014, Pages 1418-1429

  Burd, Christin E ^a   Liu, Wenjin ^b   Huynh, Minh V ^b   Waqas, Meriam A ^a   Gillahan, James E ^a   Clark, Kelly S ^b   Fu, Kailing ^b   Martin, Brit L ^a   Jeck, William R ^b   Souroullas, George P ^b   Darr, David B ^b   Zedek, Daniel C ^b   Miley, Michael J ^b   Baguley, Bruce C ^c   Campbell, Sharon L ^b   Sharpless, Norman E ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; PROTEIN KINASE LKB1; PUROMYCIN; RAF PROTEIN; RAS PROTEIN; SOS PROTEIN; TYROSINASE RELATED PROTEIN 1; CODON; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CIRCULAR DICHROISM; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENETIC STABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; MELANOCYTE; MELANOMA; MELANOMA METASTASIS; MELTING POINT; MOUSE; NEWBORN; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SOUTHERN BLOTTING; ALLELE; ANIMAL; CELL TRANSFORMATION; GENE DELETION; GENE LOCUS; GENE ORDER; GENETICS; METABOLISM; METASTASIS; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ALLELES; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CODON; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE DELETION; GENE ORDER; GENES, RAS; GENETIC LOCI; GENOTYPE; GUANOSINE TRIPHOSPHATE; HUMANS; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR BURDEN;

EID: 84964315916     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0729     Document Type: Article

References (62)

1. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945 - 50.
2. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401 - 4.
3. Adari H, Lowy DR, Willumsen BM, Der CJ, McCormick F. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 1988; 240: 518 - 21.
4. Frech M, Darden TA, Pedersen LG, Foley CK, Charifson PS, Anderson MW, et al. Role of glutamine-61 in the hydrolysis of GTP by p21Hras: an experimental and theoretical study. Biochemistry 1994; 33: 3237 - 44.
5. Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Cruger D, et al. The importance of KRAS mutations and EGF61AaG polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009; 20: 879 - 84.
6. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992 - 5.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757 - 65.
8. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374 - 9.
9. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570 - 7.
10. Chen J, Ye Y, Sun H, Shi G. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 2013; 71: 265 - 72.
11. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, Tang JL. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 2013; 119: 714 - 21.
12. Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 2012; 131: 980 - 6.
13. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812 - 20.
14. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104: 228 - 39.
15. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251 - 63.
16. Omerovic J, Prior IA. Compartmentalized signalling: Ras proteins and signalling nanoclusters. FEBS J 2009; 276: 1817 - 25.
17. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008; 40: 600 - 8.
18. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375 - 87.
19. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, et al. Somatic p16(INK4a) loss accelerates melanomagenesis . Oncogene 2010; 29: 5809 - 17.
20. Bosenberg M, Muthusamy V, Curley DP, Wang Z, Hobbs C, Nelson B, et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 2006; 44: 262 - 7.
21. Hearing VJ. Antibodies specific to melanocyte-specific proteins available from the Hearing Laboratory. Pigment Cell Melanoma Res 2009; 22: 1.
22. Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, et al. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell Melanoma Res 2014; 27: 653 - 63.
23. Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, et al. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 2012; 21: 751- 64.
24. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997; 11: 2468 - 81.
25. Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, et al. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood 2011; 117: 2022- 32.
26. Damsky WE Jr, Bosenberg M. Mouse melanoma models and cell lines. Pigment Cell Melanoma Res 2010; 23: 853 - 9.
27. Rowan A, Bataille V, MacKie R, Healy E, Bicknell D, Bodmer W, et al. Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J Invest Dermatol 1999; 112: 509 - 11.
28. Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Z euthen J. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/ STK11, in malignant melanoma. Oncogene 1999; 18: 1777 - 80.
29. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE 2009; 4: e4771.
30. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33: 237 - 47.
31. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, et al. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002; 419: 162 - 7.
32. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998; 273: 24052 - 6.
33. Voice JK, Klemke RL, Le A, Jackson JH. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem 1999; 274: 17164 - 70.
34. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001; 276: 15609 - 15.
35. Quinlan MP, Quatela SE, Philips MR, Settleman J. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol 2008; 28: 2659 - 74.
36. Buhrman G, Wink G, Mattos C. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure 2007; 15: 1618- 29.
37. Pedersen M, Kusters-Vandevelde HV, Viros A, Groenen PJ, Sanchez- Laorden B, Gilhuis JH, et al. Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes. Cancer Discov 2013; 3: 458 - 69.
38. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nrasdriven hematopoietic transformation. Cancer Discov 2013; 3: 993- 1001.
39. Jonsson A, Tuominen R, Grafstrom E, Hansson J, Egyhazi S. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol 2010; 130: 2809 - 17.
40. Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003; 95: 790- 8.
41. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012; 18: 1503 - 10.
42. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
43. Kim WY, Sharpless NE. Drug efficacy testing in mice. Current Top Microbiol Immunol 2012; 355: 19 - 38.
44. Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, et al. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. Oncologist 2012; 17: 1303 - 16.
45. Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res 2013; 19: 4889 - 99.
46. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005; 65: 4005 - 11.
47. VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL. Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell Melanoma Res 2010; 23: 531 - 41.
48. Der CJ, Finkel T, Cooper GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 1986; 44: 167 - 76.
49. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002; 1602: 23 - 45.
50. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, et al. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 2013; 123: 2078 - 93.
51. Stones CJ, Kim JE, Joseph WR, Leung E, Marshall ES, Finlay GJ, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet 2013; 4: 66.
52. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A 2013; 110: 4015 - 20.
53. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009; 28: 85 - 94.
54. Molhoek KR, Brautigan DL, Slingluff CL. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005; 3: 39.
55. Houghton AN, Albino AP, Cordon-Cardo C, Davis LJ, Eisinger M. Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med 1988; 167: 197 - 212.
56. Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, et al. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res 2007; 67: 1502 - 12.
57. Sondermann H, Soisson SM, Boykevisch S, Yang SS, Bar-Sagi D, Kuriyan J. Structural analysis of autoinhibition in the Ras activator Son of sevenless. Cell 2004; 119: 393 - 405.
58. Lenzen C, Cool RH, Wittinghofer A. Analysis of intrinsic and CDC25-stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by fluorescence measurements. Methods Enzymol 1995; 255: 95 - 109.
59. Herrmann C, Martin GA, Wittinghofer A. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 1995; 270: 2901 - 5.
60. Herrmann C, Horn G, Spaargaren M, Wittinghofer A. Differential interaction of the ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor. J Biol Chem 1996; 271: 6794 - 800.
61. Gu H, Lalonde S, Okumoto S, Looger LL, Scharff-Poulsen AM, Grossman AR, et al. A novel analytical method for in vivo phosphate tracking . FEBS Lett 2006; 580: 5885 - 93.
62. Shutes A, Der CJ. Real-time in vitro measurement of intrinsic and Ras GAP-mediated GTP hydrolysis. Methods Enzymol 2006; 407: 9 - 22.